- Ireland
- /
- Healthcare Services
- /
- ISE:UPR
The Uniphar plc (ISE:UPR) Full-Year Results Are Out And Analysts Have Published New Forecasts
Last week, you might have seen that Uniphar plc (ISE:UPR) released its annual result to the market. The early response was not positive, with shares down 3.8% to €3.18 in the past week. Uniphar reported in line with analyst predictions, delivering revenues of €2.1b and statutory earnings per share of €0.17, suggesting the business is executing well and in line with its plan. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
See our latest analysis for Uniphar
Taking into account the latest results, the most recent consensus for Uniphar from seven analysts is for revenues of €2.37b in 2023 which, if met, would be a notable 15% increase on its sales over the past 12 months. Before this earnings report, the analysts had been forecasting revenues of €2.36b and earnings per share (EPS) of €0.19 in 2023. So we can see that while the consensus made no real change to its revenue estimates, it also no longer provides an earnings per share estimate, suggesting that revenues are what the market is focusing on after the latest results.
There's been no real change to the consensus price target of €4.42, with Uniphar seemingly executing in line with expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Uniphar, with the most bullish analyst valuing it at €4.60 and the most bearish at €4.00 per share. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.
Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Uniphar's rate of growth is expected to accelerate meaningfully, with the forecast 15% annualised revenue growth to the end of 2023 noticeably faster than its historical growth of 9.8% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 5.5% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Uniphar to grow faster than the wider industry.
The Bottom Line
The clear take away from these updates is that the analysts made no change to their revenue estimates for next year, with the business apparently performing in line with their models. Fortunately, they also reconfirmed their revenue numbers, suggesting sales are tracking in line with expectations - and our data suggests that revenues are expected to grow faster than the wider industry. The consensus price target held steady at €4.42, with the latest estimates not enough to have an impact on their price targets.
We have estimates for Uniphar from its seven analysts out to 2025, and you can see them free on our platform here.
Even so, be aware that Uniphar is showing 1 warning sign in our investment analysis , you should know about...
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ISE:UPR
Uniphar
Operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, The Netherlands, and internationally.
Adequate balance sheet and fair value.